Eli Lilly (NYSE: LLY) posted $20.64 billion in net income for fiscal 2025, nearly double the prior year. The company's market cap sits at roughly $970 billion as of February 2026, making it the world's most valuable pharmaceutical company.
Earnings of Eli Lilly
Annual Earnings Of Eli Lilly
| Year | Earnings (Pretax) | YoY Change |
|---|---|---|
| 2025 | $25.73 B | +102.92% |
| 2024 | $12.68 B | +93.46% |
| 2023 | $6.55 B | -3.70% |
| 2022 | $6.80 B | +10.57% |
| 2021 | $6.15 B | -14.86% |
| 2020 | $7.22 B | +37.30% |
| 2019 | $5.26 B | +42.81% |
| 2018 | $3.68 B | +67.81% |
| 2017 | $2.19 B | -34.87% |
| 2016 | $3.37 B | +20.93% |
Eli Lilly P/E Ratio
| Year | P/E Ratio | YoY Change |
|---|---|---|
| 2025 | 44.4x | -31.90% |
| 2024 | 65.2x | -36.08% |
| 2023 | 102.0x | +91.32% |
| 2022 | 53.3x | +18.18% |
| 2021 | 45.1x | +81.85% |
| 2020 | 24.8x | +73.43% |
| 2019 | 14.3x | -57.94% |
| 2018 | 34.0x | N/A |
| 2017 | Negative | N/A |
| 2016 | 25.7x | -21.55% |
